The Effect of Antiamoebic Agents on Viability, Proliferation and Migration of Human Epithelial Cells, Keratocytes and Endothelial Cells, In Vitro

References

• Niederkorn H, Alizadeh H, Leher JP. The pathogenesis of acanthamoeba keratitis. Microbes Infect. 1999;1:437–43.
   PubMed Web of Science ®Google Scholar
• Mathers WD. Acanthamoeba: a difficult pathogen to evaluate and treat. Cornea. 2004;23:325.
   PubMed Web of Science ®Google Scholar
• Panjwani N. Pathogenesis of acanthamoeba keratitis. Ocul Surf. 2010;8:70–79.
   PubMed Web of Science ®Google Scholar
• Szentmáry N, Daas L, Matoula P, Goebels S, Seitz B. Akanthamöbenkeratitis. Ophthalmologe. 2013;110:1203–10.
   PubMed Web of Science ®Google Scholar
• Seal D, Hay J, Kirkness C, Morrell A, Booth A, Tullo A, Ridgway A, Armstrong M. Successful medical therapy of acanthamoeba keratitis with topical chlorhexidine and propamidine. Eye. 1996;10:413–21.
   PubMed Web of Science ®Google Scholar
• Daas L, Szentmáry N, Eppig T, Langenbucher A, Hasenfus A, Roth M, Saeger M, Nölle B, Lippmann B, Böhringer D, et al. Das deutsche akanthamöbenkeratitis-register - erste ergebnisse einer multizentrischen erhebung. Ophthalmologe. 2015;112:752–63.
   PubMed Web of Science ®Google Scholar
• Johns KJ, Head WS, O’Day DM. Corneal toxicity of propamidine. Arch Ophthalmol. 1988;106:68–69.
   PubMedGoogle Scholar
• Lee JE, Oum BS, Choe HY, Yu HS, Lee JS. Cysticidal effect on acanthamoeba and toxicity on human keratocytes by polyhexamethylene biguanide and chlorhexidine. Cornea. 2007;26:736–41.
   PubMed Web of Science ®Google Scholar
• Mafra CSP, Carrjio-Carvalho LC, Chudzinski-Tavassi AM, Taguchi FM, Foronda AS, Carvalho FR, de Freitas D. Antimicrobial action of biguanides on the viability of acanthamoeba cysts and assessment of cell toxicity. Iovs. 2013;54:6363–72.
   PubMed Web of Science ®Google Scholar
• Shigeyasu C, Shimazaki J. Ocular surface reconstruction after exposure to high concentrations of antiseptic solutions. Cornea. 2012;31:59–65.
   PubMed Web of Science ®Google Scholar
• Hager T, Hasenfus A, Stachon T, Seitz B, Szentmáry N. Crosslinking and corneal cryotherapy in acanthamoeba keratitis - a histological study. Graefes Arch Clin Exp Ophthalmol. 2016;254:149–53.
   PubMed Web of Science ®Google Scholar
• Iovieno A, Oechsler RA, Ledee DR, Miller D, Alfonso EC. Drug-resistant severe acanthamoeba keratitis caused by rare T5 acanthamoeba genotype. Eye Contact Lens. 2010;36:183–84.
   PubMed Web of Science ®Google Scholar
• Arnalich-Montiel F, Lumbreras-Fernández B, Martín-Navarro CM, Valladares B, Lopez-Velez R, Morcillo-Laiz R, Lorenzo-Morales J. Influence of acanthamoeba genotype on clinical course and outcomes for patients with acanthamoeba keratitis in Spain. J Clin Microbiol. 2014;52:1212–16.
   Web of Science ®Google Scholar
• Sunada A, Kimura K, Nishi I, Toyokawa M, Ueda A, Sakata T, Suzuki T, Inoue Y, Ohashi Y, Asari S, et al. In vitro evaluations of topical agent to treat acanthamoeba keratitis. Ophthalmology. 2014;121:2059–65.
   PubMed Web of Science ®Google Scholar
• Wright P, Warhurst D, Jones BR. Acanthamoeba keratitis successfully treated medically. Br J Ophthalmol. 1985;69:778–82.
   PubMed Web of Science ®Google Scholar
• Brasseur G, Favennec L, Perrine D, Chenu JP, Brasseur P. Successful treatment of acanthamoeba keratitis by hexamidine. Cornea. 1994;13:459–62.
   PubMed Web of Science ®Google Scholar
• Perrine D, Chenu JP, Georges P, Lancelot JC, Saturnino C, Robba M. Amoebicidal efficiencies of various diamidines against two strains of acanthamoeba polyphaga. Antimicrob Agents Chemother. 1995;39:339–42.
   PubMed Web of Science ®Google Scholar
• Khunkitti W, Avery SV, Lloyd D, Furr JR, Russell AD. Effects of biocides on acanthamoeba castellanii as measured by flow cytometry and plaque assay. J Antimicrob Chemother. 1997;40:227–33.
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Abdel Aziz S, Romanowski EG, Shanks RM, Nau AC, Raju LV. Development of a practical complete-kill assay to evaluate anti-acanthamoeba drugs. JAMA Ophthalmol. 2013;131:1459–62.
   PubMed Web of Science ®Google Scholar
• Lim N, Goh D, Bunce C, Xing W, Fraenkel G, Poole TR, Ficker L. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of acanthamoeba keratitis. Am J Ophthalmol. 2008;145:130–35.
   PubMed Web of Science ®Google Scholar
• Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol. 2009;148(4):487–99.
   PubMed Web of Science ®Google Scholar
• Moon EK, Hong Y, Chung DI, Goo YK, Kong HH. Potential value of cellulose synthesis inhibitors combined with PHMB in the treatment of acanthamoeba keratitis. Cornea. 2015;34:1593–98.
   PubMed Web of Science ®Google Scholar
• Mathers W. Use of higher medication concentrations in the treatment of acanthamoeba keratitis. Arch Ophthalmol. 2006;124:923.
   PubMedGoogle Scholar
• Narasimhan S, Madhavan HNKLT. Development and application of an in vitro susceptibility test for acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine. Cornea. 2002;21:203–05.
   PubMed Web of Science ®Google Scholar
• Turner NA, Russell AD, Furr JR, Lloyd D. Emergence of resistance to biocides during differentiation of acanthamoeba castellanii. J Antimicrob Chemother. 2000;46:27–34.
   PubMed Web of Science ®Google Scholar
• Alkharashi M, Lindsley K, Law HA, Sikder S. Medical interventions for acanthamoeba keratitis. Cochrane Database Syst Rev. 2015;24(2):CD010792.
   Google Scholar
• Fernández-Ferreiro A, Santiago-Varela M, Gil-Martínez M. In vitro evaluation of the ophthalmic toxicity profile of chlorhexidine and propamidine isethionate eye drops. J Ocul Pharmacol Ther. 2017;33:202–09.
   PubMed Web of Science ®Google Scholar
• Vontobel SF, Abad-Villar EM, Kaufmann C, Zinkernagel AS, Hauser PC, Thiel MA. Corneal penetration of polyhexamethylene biguanide and chlorhexidine digluconate. Clin Exp Ophthalmol. 2015;6:1000430.
   Google Scholar
• Murthy S, Hawksworth NR, Cree I. Progessive ulcerative keratitis related to the use of topical chlorhexidine gluconate (0.02%). Cornea. 2002;21:237–39.
   PubMed Web of Science ®Google Scholar
• Ehlers N, Hjortdal J. Are cataract and iris atrophy toxic complications of medical treatment of acanthamoeba keratitis? Acta Ophthalmol Acand. 2004;82:228–31.
   PubMed Web of Science ®Google Scholar
• Awwad ST, Heilman M, Hogan RN, Parmar DN, Petroll WM, McCulley JP, Cavanagh HD. Severe reactive ischemic posterior segment inflammation in acanthamoeba keratitis; a new potentially blinding syndrome. Ophthalmology. 2007;114:313–20.
   PubMed Web of Science ®Google Scholar
• Duguid IG, Dart JK, Morlet N, Allan BD, Matheson M, Ficker L, Tuft S. Outcome of acanthamoeba keratitis treated with polyhexamethyl biguainide and propamidine. Ophthalmology. 1997;104:1587–92.
   PubMed Web of Science ®Google Scholar
• Herz NL, Matoba AY, Wilhelmus KR. Rapidly progressive cataract and iris atrophy during treatment of acanthamoeba keratitis. Ophthalmology. 2008;115:866–69.
   PubMed Web of Science ®Google Scholar